NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Vericel Corporation (VCEL) Stock Analysis

Vericel Corporation (VCEL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VCEL

$40.19

−$0.28 (−0.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VCEL with… →

VCEL Key Statistics

As of Sep 4, 2026
Trading
Open
$40.04
Previous Close
$40.47
Day's Range
39.85–40.57
52-Week Range
28.95–49.32
Volume
312.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$2.06B
P/E Ratio
83.73
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
47.51
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.72
EPS (ttm)Profit attributable to each share over the last twelve months.
0.48
Financials (FY)
Revenue (FY)
$276.26M+16.45%
Net Income (FY)
$16.52M+59.41%
Profit marginThe share of revenue left as profit after all costs and taxes.
7.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.21M
1-Year Return
+19.36%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
567.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VCEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+11.61%
2025−34.42%
2024+54.20%
2023+35.19%
2022−32.98%
2021+27.27%
2020+77.47%
2019+0.00%
2018+219.27%
2017+81.67%
2016 (partial year)+31.58%

As of September 4, 2026.

VCEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$276.26M$16.52M6.0%
2024$237.22M$10.36M4.4%
2023$197.52M−$3.18M−1.6%
2022$164.37M−$16.71M−10.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$276.26M$205.60M$11.04M$16.52M6.0%
2024$237.22M$172.11M$4.52M$10.36M4.4%
2023$197.52M$135.58M−$6.46M−$3.18M−1.6%
2022$164.37M$109.79M−$17.06M−$16.71M−10.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VCEL Valuation vs Biotechnology Median

Median of 656 stocks
MetricVCELBiotechnology medianvs median
P/E83.7312.576.7x the median
P/S ratio6.7215.2656% below
Profit margin7.91%0.00%7.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vericel Corporation (VCEL) is capitalised at $2.06B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 398.

Over the past 52 weeks the price has ranged from $28.95 to $49.32. VCEL last closed at $40.19 on September 4, 2026. That is −$0.28 (−0.69%) against the previous close. The latest close sits 38.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $276.26M. That is +16.45% against the prior fiscal year, when revenue was $237.22M. The same year closed with net income of $16.52M. That is +59.41% against the prior fiscal year. The reported profit margin is 7.91%. That is 7.9 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.48.

Across the 4 fiscal years on file, revenue moves from $164.37M in 2022 to $276.26M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

VCEL trades at a trailing price-to-earnings ratio of 83.73. That is 6.7 times the Biotechnology median of 12.57. On forward earnings the ratio is 47.51. The price-to-sales ratio is 6.72. On price-to-sales that is 55.98% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +19.36%. Measured over 10 years, that is +33.41% a year compounded. The reported beta is 1.05. Annualized volatility over the trailing 10 years is 62.91%.

Growth & Income

The record shows no dividend for VCEL.

The strongest complete calendar year on file is 2018 at +219.27%; the weakest is 2025 at −34.42%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +11.61% year to date.

Peer Comparison

Vericel Corporation (VCEL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vericel Corporation VCEL $2.06B 83.7
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Vericel Corporation trades at a P/E of 83.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Visit website →